- Home
- ALLT vs ATYR Comparison
ALLT vs ATYR Comparison
Compare ALLT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- ATYR
- Stock Information
- Founded
- ALLT 1996
- ATYR 2005
- Country
- ALLT Israel
- ATYR United States
- Employees
- ALLT N/A
- ATYR N/A
- Industry
- ALLT Telecommunications Equipment
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLT Telecommunications
- ATYR Health Care
- Exchange
- ALLT Nasdaq
- ATYR Nasdaq
- Market Cap
- ALLT 269.5M
- ATYR 228.1M
- IPO Year
- ALLT 2006
- ATYR 2015
- Fundamental
- Price
- ALLT $7.81
- ATYR $3.63
- Analyst Decision
- ALLT Buy
- ATYR Strong Buy
- Analyst Count
- ALLT 1
- ATYR 5
- Target Price
- ALLT $13.00
- ATYR $19.25
- AVG Volume (30 Days)
- ALLT 1.1M
- ATYR 960.8K
- Earning Date
- ALLT 02-25-2025
- ATYR 03-13-2025
- Dividend Yield
- ALLT N/A
- ATYR N/A
- EPS Growth
- ALLT N/A
- ATYR N/A
- EPS
- ALLT N/A
- ATYR N/A
- Revenue
- ALLT $91,631,000.00
- ATYR $235,000.00
- Revenue This Year
- ALLT $0.41
- ATYR N/A
- Revenue Next Year
- ALLT $8.84
- ATYR $1,080.92
- P/E Ratio
- ALLT N/A
- ATYR N/A
- Revenue Growth
- ALLT N/A
- ATYR N/A
- 52 Week Low
- ALLT $1.61
- ATYR $1.42
- 52 Week High
- ALLT $8.15
- ATYR $4.23
- Technical
- Relative Strength Index (RSI)
- ALLT 71.69
- ATYR 53.70
- Support Level
- ALLT $6.51
- ATYR $3.17
- Resistance Level
- ALLT $7.76
- ATYR $3.83
- Average True Range (ATR)
- ALLT 0.69
- ATYR 0.25
- MACD
- ALLT 0.05
- ATYR -0.02
- Stochastic Oscillator
- ALLT 86.03
- ATYR 43.60
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. It has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.